Recent Updates
Recently added Catalysts
OBX Positive Sentiment

Obsidian Therapeutics to Present Updated Amsoki-cel (OBX-115) Phase 1/2 Data in Advanced Melanoma at SITC 2026 Annual Meeting

Friday, October 2, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Obsidian Therapeutics has announced a poster presentation of updated data on amsoki-cel for patients with immune-checkpoint inhibitor-resistant advanced melanoma. This data is derived from both a Phase 1 single-center first-in-human study and a Phase 1/2 multicenter study. The presentation will take place at the SITC 2026 Annual Meeting.

Market Sentiment Analysis

POSITIVE FACTORS

  • Obsidian Therapeutics presents updated data on amsoki-cel.
  • The study focuses on patients with advanced melanoma.
  • The data comes from a first-in-human study and a multicenter study.

Full Press Release Details

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Obsidian Therapeutics, Inc. (“Obsidian”) (Nasdaq: OBX), a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor-infiltrating lymphocyte (TIL) cell therapies, today announced a poster presentation of updated data in patients with immune-checkpoint inhibitor (ICI)-resistant advanced melanoma from the Phase 1 single-center first-in-human (FIH) study and the Phase 1/2 Agni-01 multicenter study of amsoki

Frequently Asked Questions

What is amsoki-cel?

Amsoki-cel is an engineered tumor-infiltrating lymphocyte cell therapy.

What type of cancer is being studied?

The study focuses on advanced melanoma resistant to immune-checkpoint inhibitors.

When will the data be presented?

The updated data will be presented at the SITC 2026 Annual Meeting.

What studies are involved in the presentation?

The data comes from a Phase 1 single-center study and a Phase 1/2 multicenter study.

ShareAdd on Google
Tags: OBX Obsidian Therapeutics advanced melanoma Phase 1 Phase 1/2 SITC 2026
Last updated: Oct 2, 2026

Biotech snapshot

Cash runway
$0M liquidity · $0M/mo burn
Low dilution risk